Maryann San Martin

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies

Bernard Barlaam, Robert Casella, Justin Cidado et al. · Journal of Medicinal Chemistry · 2020 · 104 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

Anna D. Staniszewska, Joshua Armenia, Matthew King et al. · OncoImmunology · 2022 · 49 citations · Full text

Life Sciences, Immunology, Oncology +17

Discovery of Inhibitors of 4′-Phosphopantetheine Adenylyltransferase (PPAT) To Validate PPAT as a Target for Antibacterial Therapy

Boudewijn L. M. de Jonge, Grant K. Walkup, Sushmita D. Lahiri et al. · Antimicrobial Agents and Chemotherapy · 2013 · 44 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

Scott Boiko, Theresa A. Proia, Maryann San Martin et al. · Blood · 2020 · 30 citations · Full text

Medicine, Cancer Biology, Oncology +6

Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model

Renu Singh, Mashal M. Almutairi, Richard A. Alm et al. · Journal of Antimicrobial Chemotherapy · 2017 · 24 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16